Last reviewed · How we verify
AST2818 Tablets
At a glance
| Generic name | AST2818 Tablets |
|---|---|
| Sponsor | Allist Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (PHASE3)
- Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (PHASE1)
- Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) (PHASE3)
- An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
- Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC (PHASE2)
- Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities (PHASE2)
- Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AST2818 Tablets CI brief — competitive landscape report
- AST2818 Tablets updates RSS · CI watch RSS
- Allist Pharmaceuticals, Inc. portfolio CI